At What Price Is Canopy Growth (TSX:WEED) Stock Worth Buying?

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is the king of the cannabis castle, but is it really worth the price it currently trades for?

| More on:

Lately, it’s been quiet on the Canopy Growth Corp (TSX:WEED)(NYSE:CGC) front. The marijuana stock that previously had a beta coefficient higher than 4, has been stable around $60 for weeks. So far this year, the stock has risen about 54%, but the majority of those gains were locked in by January 30. Since then, the stock has been trading in a $6 price range and holding steady.

The fact that Canopy is now fairly flat may indicate that speculators have lost interest in the stock, and that most people holding it are in for the long term. If that’s the case, the usual price and value calculations now apply to Canopy–which in the past was a pure momentum play.

To gauge what price Canopy is worth today, we need to look at how the company is doing relative to its fundamentals.

Valuation

Canopy has historically been a pretty expensive stock, trading at up to 200 times sales. For the recent 12-month period, Canopy traded at 136 times sales, which is still very high. For the same period, earnings were negative. It is possible to calculate a “P/E ratio” for the most recent quarter: using the basic EPS figure ($0.22), it’s about 272. However, P/E ratios are usually calculated with 12-month data or forward projections, so this isn’t a conventional approach.

The big takeaway is that Canopy is very expensive relative to sales and earnings. However, this may not make the stock overvalued if we take growth into consideration as well.

Growth

As you might know, a high P/E ratio does not necessarily mean a stock is overvalued. If growth is high, a P/E ratio may be high (and justified) as well. A great example of this would be Amazon.com, whose P/E ratio has historically hovered over 100 without harming the stock’s return at all.

Currently, Canopy is growing even faster than Amazon at its peak, with sales up 280% and profits up 4000% year over year. That kind of growth can make a pretty high P/E ratio look insignificant in comparison. At the same time, Canopy’s recent positive earnings were because of fair value changes rather than operations; the company’s operating income was still $-78 million. This calls into question whether we’re really seeing an increasingly profitable company here, or one that got lucky one quarter.

Analyst targets

A final factor to take into account when evaluating a fair stock price is analyst targets. The world’s largest banks and mutual funds rely on analyst ratings to guide their investing decisions, so these figures are considered reliable.

According to the Wall Street Journal, the median analyst target price for Canopy is $72, while the highest is $100 and the lowest is $15. Going off the median, Canopy still has plenty of room to grow before it hits a price analysts consider fair. In light of that, now seems like a good time to buy Canopy shares. But it’s important to remember that this is a very volatile stock that has often behaved in ways that analysts didn’t expect.

Should you invest $1,000 in iShares S&P/TSX 60 Index ETF right now?

Before you buy stock in iShares S&P/TSX 60 Index ETF, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and iShares S&P/TSX 60 Index ETF wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,345.77!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 24 percentage points since 2013*.

See the Top Stocks * Returns as of 4/21/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Fool contributor Andrew Button has no position in any of the stocks mentioned. David Gardner owns shares of Amazon. The Motley Fool owns shares of Amazon.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

Buy the Dip Before It’s Too Late: This Canadian Stock Won’t Stay Cheap Forever

Investors might think that cannabis stocks are out, but this one could be the top Canadian stock to consider.

Read more »

a person watches a downward arrow crash through the floor
Stocks for Beginners

Plummet Alert: Is This TSX Growth Stock a Bargain or a Falling Knife?

This growth stock was once a major winner, but can investors wait for more?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

What to Know About Canadian Cannabis Stocks for 2025

Let's dive into two top Canadian cannabis stocks and where they may be headed from here (given the recent moves…

Read more »

Researcher works in hemp field
Cannabis Stocks

Aurora Cannabis Stock Is up 46% in 2025: Are Investors Going From 5 Years of Pain to a 2025 Gain?

Shares of Aurora Cannabis have staged a comeback in 2025, outpacing the broader markets comfortably. Is ACB stock a good…

Read more »

A plant grows from coins.
Stocks for Beginners

3 Growth Stocks That Could Skyrocket in 2025 and Beyond

It could be a big year for these sectors, and these growth stocks in particular throughout 2025.

Read more »

money goes up and down in balance
Tech Stocks

2 TSX Stocks to Buy and 2 to Avoid in the Looming Trade War

The looming U.S.-Canada trade war has changed the business environment. Here are some TSX stocks to buy and avoid in…

Read more »

space ship model takes off
Cannabis Stocks

2 Canadian Stocks With Strong Momentum for 2025

Celestica Inc. (TSX:CLS) stock and Dollarama (TSX:DOL) stock have sustained strong price growth momentum for a long time.  Here’s why…

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Pot Stocks: Buy, Sell, or Hold in 2025?

Cannabis stocks remain a bit risky, but could long-term investors be in for more pain or far more profits?

Read more »